Spondyloarthropathies News

Imaging changes indicative of axial spondyloarthritis occurred frequently in patients with fibromyalgia, which suggested hidden axial spondyloarthritis may be masked by fibromyalgia, according to results of a recently published study.

Today, the FDA has approved Merck and Samsung Bioepis’ infliximab biosimilar for injection, which is known as infliximab-abda (Renflexis). It will maintain the same indications as the reference product.

Patients with inflammatory arthritis who underwent total hip arthroplasty experienced higher rates of complications compared with patients who had osteoarthritis, according to results.

Massage therapy was beneficial to patients with chronic back pain, according to research recently published in Pain Management.

CLEVELAND — Christopher Ritchlin, MD, MPH, professor of medicine at the University of Rochester Medical Center, reviewed treatments for psoriatic arthritis, spondyloarthritis and other spondyloarthropathies at the Primary Vasculitides Pre-symposium of the Biologic Therapies VII Summit.

Investigators of this cross-sectional study found psoriasis and psoriatic arthritis correlated with pathologic fractures and other bone-related conditions.

There was minimal to no transfer of Cimzia from nursing mothers to breast milk, considered to be an acceptable range for breast-feeding, according to a poster presentation at the American Academy of Dermatology Annual Meeting in Orlando, Florida.

The European Commission has approved Amgevita, a biosimilar to adalimumab, for the treatment of moderate to severe rheumatoid arthritis, psoriatic arthritis, severe active ankylosing spondylitis, severe axial spondyloarthritis without radiographic evidence of ankylosing spondylitis in addition to moderate to severe chronic plaque psoriasis, moderate-to-severe hidradenitis suppurativa, non-infectious intermediate, posterior and panuveitis, moderate to severe Crohn’s disease and moderate to severe ulcerative colitis. It is also approved for Crohn’s disease in children aged 6 years and older, severe chronic plaque psoriasis in children aged 4 years and older, enthesitis-related arthritis in children aged 6 years and older and polyarticular juvenile idiopathic arthritis in children aged 2 years and older.

NEW YORK — At the Interdisciplinary Autoimmune Summit, Atul A. Deodhar, MD, professor of medicine and medical director at the Oregon Health and Science University, spoke about the integration of care in spondyloarthritis to ensure that these patients are not being missed.

Many patients with moderate-to-severe psoriasis retreated with Consentyx regained previous levels of efficacy after 16 weeks following a relapse during a treatment pause, according to a poster presentation at the American Academy of Dermatology Annual Meeting in Orlando, Florida.